Literature DB >> 24870871

A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24870871

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  11 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  A Review of Autologous Stem Cell Transplantation in Lymphoma.

Authors:  Umar Zahid; Faisal Akbar; Akshay Amaraneni; Muhammad Husnain; Onyee Chan; Irbaz Bin Riaz; Ali McBride; Ahmad Iftikhar; Faiz Anwer
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

3.  Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.

Authors:  Zainul S Hasanali; Elliot M Epner; David J Feith; Thomas P Loughran; Clare E Sample
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

4.  Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Authors:  M Pfeifer; B Zheng; T Erdmann; H Koeppen; R McCord; M Grau; A Staiger; A Chai; T Sandmann; H Madle; B Dörken; Y-W Chu; A I Chen; D Lebovic; G A Salles; M S Czuczman; M C Palanca-Wessels; O W Press; R Advani; F Morschhauser; B D Cheson; P Lenz; G Ott; A G Polson; K E Mundt; G Lenz
Journal:  Leukemia       Date:  2015-02-24       Impact factor: 11.528

Review 5.  The landscape of new drugs in lymphoma.

Authors:  Anas Younes; Stephen Ansell; Nathan Fowler; Wyndham Wilson; Sven de Vos; John Seymour; Ranjana Advani; Andres Forero; Franck Morschhauser; Marie Jose Kersten; Kensei Tobinai; Pier Luigi Zinzani; Emanuele Zucca; Jeremy Abramson; Julie Vose
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

6.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Authors:  Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

Review 7.  Role of CD30 targeting in malignant lymphoma.

Authors:  Anita Kumar; Anas Younes
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 8.  Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.

Authors:  Dowdy Jackson; David Stover
Journal:  Pharm Res       Date:  2014-10-23       Impact factor: 4.200

Review 9.  Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

Authors:  Alexander H Staudacher; Michael P Brown
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

Review 10.  Antibody-Drug Conjugates: The Last Decade.

Authors:  Nicolas Joubert; Alain Beck; Charles Dumontet; Caroline Denevault-Sabourin
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.